Hope Thomas A, Truillet Charles, Ehman Eric C, Afshar-Oromieh Ali, Aggarwal Rahul, Ryan Charles J, Carroll Peter R, Small Eric J, Evans Michael J
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
Department of Radiology, San Francisco VA Medical Center, San Francisco, California.
J Nucl Med. 2017 Jan;58(1):81-84. doi: 10.2967/jnumed.116.181800. Epub 2016 Sep 22.
The purpose of this work was to evaluate the effect of androgen receptor (AR) inhibition on prostate-specific membrane antigen (PSMA) uptake imaged using Ga-PSMA-11 PET in a mouse xenograft model and in a patient with castration-sensitive prostate cancer.
We imaged 3 groups of 4 mice bearing LNCaP-AR xenografts before and 7 d after treatment with ARN-509, orchiectomy, or control vehicle. Additionally, we imaged one patient with castration-sensitive prostate cancer before and 4 wk after treatment with androgen deprivation therapy (ADT). Uptake on pre- and posttreatment imaging was measured and compared.
PSMA uptake increased 1.5- to 2.0-fold in the xenograft mouse model after treatment with both orchiectomy and ARN-509 but not with vehicle. Patient imaging demonstrated a 7-fold increase in PSMA uptake after the initiation of ADT. Thirteen of 22 lesions in the imaged patient were visualized on PSMA PET only after treatment with ADT.
Inhibition of the AR can increase PSMA expression in prostate cancer metastases and increase the number of lesions visualized using PSMA PET. The effect seen in cell and animal models can be recapitulated in humans. A better understanding of the temporal changes in PSMA expression is needed to leverage this effect for both improved diagnosis and improved therapy.
本研究的目的是在小鼠异种移植模型和一名去势敏感性前列腺癌患者中,评估雄激素受体(AR)抑制对使用镓-PSMA-11 PET成像的前列腺特异性膜抗原(PSMA)摄取的影响。
我们对3组每组4只携带LNCaP-AR异种移植物的小鼠在接受ARN-509、去势或对照载体治疗前和治疗后7天进行成像。此外,我们对一名去势敏感性前列腺癌患者在接受雄激素剥夺治疗(ADT)前和治疗后4周进行成像。测量并比较治疗前后成像的摄取情况。
在异种移植小鼠模型中,去势和ARN-509治疗后PSMA摄取增加了1.5至2.0倍,而载体治疗后未增加。患者成像显示ADT开始后PSMA摄取增加了7倍。成像患者的22个病灶中,有13个仅在ADT治疗后通过PSMA PET显影。
AR抑制可增加前列腺癌转移灶中PSMA的表达,并增加使用PSMA PET显影的病灶数量。在细胞和动物模型中观察到的效应在人类中也可重现。需要更好地了解PSMA表达的时间变化,以利用这种效应改善诊断和治疗。